A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
NCT ID: NCT00250575
Last Updated: 2016-04-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
43 participants
INTERVENTIONAL
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is not recruiting in the United States.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169039
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05958875
Therapeutic Drug Monitoring for Individualized Clozapine Therapy
NCT03523741
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
NCT00482430
An Exploratory Analysis of Immune and Inflammatory Response Associated with Clozapine
NCT05741502
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Clozapine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clozapine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Not responded to at least two atypical antipshychotics launched in Japan
* Inpatient
Exclusion Criteria
* Significant heart diseases
* Diabetes mellitus
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_CHAIR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigational Site
Chiba, , Japan
Novartis Investigative Site
Fukuoka, , Japan
Novartis Investigative Site
Ishikawa, , Japan
Novartis Investigative Site
Osaka, , Japan
Novartis Investigative Site
Saga, , Japan
Novartis Investigative Site
Tokyo, , Japan
Novartis Investigative Site
Toyama, , Japan
Novartis Investigative Site
Yamanashi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLEX123J1301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.